deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT01647308

Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Sponsor: Ionis Pharmaceuticals, Inc.

Conditions Type 2 Diabetes
Interventions ISIS-APOCIIIRX Placebo
Updated 13 times since 2017 Last updated: Jan 13, 2022 Started: Jul 31, 2012 Primary completion: Jan 31, 2014 Completion: Mar 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated for business planning purposes. Assessments of APOCIIIRx in this population will be explored in a larger efficacy study

Other terminated trials from Ionis Pharmaceuticals, Inc.

More terminations from Ionis Pharmaceuticals, Inc.

Other Type 2 Diabetes trials with similar outcome

Browse all Type 2 Diabetes trials

Listed as NCT01647308, this PHASE2 trial focuses on Type 2 Diabetes and remains terminated or withdrawn. Sponsored by Ionis Pharmaceuticals, Inc., it has been updated 13 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~May 2018 · 9 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2020 · 28 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Feb 2022 — Apr 2022 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Feb 2022 [monthly]

    Terminated PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Jul 2018 — Nov 2020 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jul 2018 [monthly]

    Terminated PHASE2

  5. May 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  6. Aug 2017 — May 2018 [monthly]

    Terminated PHASE2

  7. Feb 2017 — Aug 2017 [monthly]

    Terminated PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ionis Pharmaceuticals, Inc.
Data source: Ionis Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations